Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02302079 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate ASP8232 in Reducing Central Retinal Thickness in Subjects With Diabetic Macular Edema (DME)
A Phase 2 study, sponsored by Astellas Pharma Europe B.V..
- Completed
- Registry status
- Phase 2
- Development phase
- 96
- Enrollment target
NCT02302079 is a Phase 2 study that has completed, run by Astellas Pharma Europe B.V.. The registered enrollment target is 96 participants.
The verdict
NCT02302079, a Phase 2 study, has completed, sponsored by Astellas Pharma Europe B.V..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 96 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate efficacy and safety of ASP8232 in subjects with diabetic macular edema (DME). This study will evaluate the percent change from baseline in excess central subfield thickness (CST) in the study eye as assessed by spectral domain-optical coherence Tomography (SD-OCT) for ASP8232 monotherapy at Month 3.
Interventions
- DRUG Placebo
- DRUG ranibizumab
- DRUG ASP8232
- OTHER Sham intravitreal (IVT) injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 96 participants |
| Start Date | 2015-01-12 |
| Est. Completion | 2016-08-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02302079
The ClinicalTrials.gov registry entry for NCT02302079 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 96 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma Europe B.V., which has 12 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02302079 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02302079 about?
NCT02302079 is a clinical study titled "A Study to Evaluate ASP8232 in Reducing Central Retinal Thickness in Subjects With Diabetic Macular Edema (DME)". The purpose of this study is to evaluate efficacy and safety of ASP8232 in subjects with diabetic macular edema (DME). This study will evaluate the percent change from baseline in excess central subfield thickness (CST) in the study eye as assessed by spectral domain-optical coherence Tomography (SD...
What is the current status of trial NCT02302079?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 96 participants. The study started on 2015-01-12. Estimated completion is 2016-08-12.
What interventions are being tested in trial NCT02302079?
The interventions under investigation include: Placebo (DRUG), ranibizumab (DRUG), ASP8232 (DRUG), Sham intravitreal (IVT) injection (OTHER).
Who is sponsoring clinical trial NCT02302079?
This trial is sponsored by Astellas Pharma Europe B.V., which has 12 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.